Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xilio Therapeutics (XLO) EPS (Weighted Average and Diluted) (2024 - 2025)

Historic EPS (Weighted Average and Diluted) for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$0.11.

  • Xilio Therapeutics' EPS (Weighted Average and Diluted) rose 5000.0% to -$0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.63, marking a year-over-year change of. This contributed to the annual value of -$1.13 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Xilio Therapeutics reported EPS (Weighted Average and Diluted) of -$0.11 as of Q3 2025, which was up 5000.0% from -$0.16 recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.11 in Q3 2025 and a low of -$0.25 during Q4 2024